8:06 am Biomarin Pharm announces selection of NAGLU fusion protein drug development candidate BMN 250 for the treatment of Sanfilippo B (MPS IIIB)
View todays social media effects on BMRN
View the latest stocks trending across Twitter. Click to view dashboard
See who BioMarin is hiring next, click here to view
